Esmolol Hydrochloride is a pharmaceutical salt formed by ionic pairing of the active pharmacophore with a carefully selected counter-ion to optimise aqueous solubility, crystallinity, dissolution rate, and solid-state stability relative to the parent free form. Salt selection is a pivotal pharmaceutical development decision influencing polymorphic landscape, hygroscopicity, powder flow, compressibility, and bioavailability. Characterisation of Esmolol Hydrochloride by XRPD, DSC, TGA, and dynamic vapour sorption is essential to define the approved solid-state form and ensure consistent quality across manufacturing batches.
The intraspecies uncertainty factor F2 for Esmolol Hydrochloride covers the range of pharmacokinetic and pharmacodynamic variability within the human population, ensuring the derived PDE is protective for sensitive subgroups including paediatric patients with immature CYP450 activity, elderly patients with reduced hepatic and renal clearance, patients with organ impa
